|Title:||Retroviral protease inhibiting compounds|
|Abstract:||A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.|
|Inventor(s):||Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing L. (Gurnee, IL), Zhao; Chen (Gurnee, IL), Reno; Daniel S. (Kenosha, WI)|
|Assignee:||Abbott Laboratories (Abbott Park, IL)|
|Filing Date:||Apr 06, 1995|
|Claims:||1. A process for the preparation of a compound of the formula: ##STR18## wherein R.sub.1 is monosubstituted thiazolyl, monosubstituted oxazolyl, monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is selected from C.sub.1 -to-C.sub.6 -loweralkyl; |
n is 1, 2 or 3;
R.sub.2 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;
R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl;
R.sub.4 and R.sub.4a are independently selected from phenyl, thiazolyl and oxazolyl wherein the phenyl, thiazolyl or oxazolyl ring is unsubstituted or substituted with a substituent selected from
(ii) C.sub.1 -to-C.sub.5 -loweralkyl,
(iv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and
(v) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-;
R.sub.6 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;
R.sub.7 is thiazolyl, oxazolyl, isoxazolyl or isothiazolyl wherein the thiazolyl, oxazolyl, isoxazolyl or isothiazolyl ring is unsubstituted or substituted with C.sub.1 -to-C.sub.6 -loweralkyl; and
Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl, C.sub.3 -to-C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; or a pharmaceutically acceptable salt thereof, comprising (a) reacting a compound of the formula: ##STR19## wherein R.sub.4 and R.sub.4a are as defined above with Ti(OR****).sub.4 wherein R**** is C.sub.1 -to-C.sub.6 -loweralkyl, followed by reaction with a compound of the formula: ##STR20## or an activated ester derivative thereof, wherein R.sub.1, R.sub.2, R.sub.3, Z and n are as defined above to give a compound of the formula: ##STR21## and (b) acylation of the product of step (a) with a compound of the formula (R.sub.6)(R.sub.7)CHOC(O)OL wherein L is an activating group for the acylation reaction and wherein R.sub.6 and R.sub.7 are defined as above.
2. The process of claim 1 wherein R.sub.1 is C.sub.1 -to-C.sub.6 -loweralkyl-substituted thiazolyl, R.sub.2 is hydrogen, R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl, R.sub.4a and R.sub.4 are phenyl, R.sub.6 is hydrogen, R.sub.7 is thiazolyl and n is 1.
3. The process of claim 1 wherein R**** is isopropyl.
4. The process of claim 1 wherein R.sub.1 is 2-isopropyl-4-thiazolyl, n is 1, R.sub.2 is hydrogen, R.sub.3 is isopropyl, R.sub.4 and R.sub.4a are phenyl, R.sub.6 is hydrogen, R.sub.7 is 5-thiazolyl, Z is --N(CH.sub.3)-- and R**** is isopropyl.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.